Ademi LLP is investigating Marinus (Nasdaq: MRNS) for possible breaches of fiduciary duty and other violations of law in its transaction with the Immedica.
In the transaction, Marinus shareholders will receive $0.55 per share. Marinus insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Marinus by imposing a significant penalty if Marinus accepts a competing bid. We are investigating the conduct of Marinus’ board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.